

FY2026 RESULTS AND BUSINESS UPDATE PRESENTATION

BRISBANE, AUSTRALIA, 30 September 2026: AnteoTech Ltd (ASX: ADO) (AnteoTech or the Company) provides the attached Full Year Results and Business Update presentation. The presentation accompanies the live webinar to be hosted by AnteoTech's Managing Director and CEO, Merrill Gray scheduled for 11am AEST on Wednesday 30 September 2026.

To register and join the webinar please use the below link.

Webinar Details

Date: **Wednesday 30 September 2026**

Time: **11:00am AEST / 9:00am AWST**

Register for the webinar:

https://us02web.zoom.us/webinar/register/WN_06ooKf_uTjeuH5fVY8kH2g

A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company's website and social media channels.

This announcement has been authorised for release by the Board of AnteoTech Ltd.

- ENDS -

Media and investor enquiries: on +61 7 3219 0085 or investors@anteotech.com

Company and Partnering enquiries: Merrill Gray, CEO/MD, on + 61 7 3219 0085

For further information, please check our website www.anteotech.com

About AnteoTech – (ASX: ADO)

AnteoTech is a supplier of advanced chemical and material solutions to the battery materials and life sciences markets. We leverage our market leading binding chemical platform technology to develop and commercialise solutions for our global customer base. From our patented high silicon anode cross linker product Anteo X™ to our ceramic coated separator product Anteo S™ and our Collector foil primer coating performance additive Anteo C through to our next-generation high silicon anode formulations Ultranode™ 70, 95 and X our Advanced Battery Technology business is applying its world-leading engineering expertise to address the growing demand for high performance, low cost, sustainable chemicals and materials within the global Lithium ion Battery market. Our Life Sciences business supplies advanced activation materials to leading developers and manufacturers of vaccines and diagnostic tests, through our AnteoBind™ suite of products. Our products deliver more sensitive and reproducible results and on incorporation in ‘point of care’ and other immunoassay diagnostic tests such as Chemiluminescence immunoassays (CLIA) and Enzyme-Linked Immunosorbent Assay (ELISA) plates, AnteoBind™ NXT enables faster, more reliable and more accurate test results wherever they are needed.

AnteoTech – Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails – visit our website at www.anteotech.com and subscribe to receive our email alert service.

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (Estimates and Projections). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regard to future events in respect to AnteoTech’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risks and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.



Investor Webinar

FY 2026 Results

Merrill Gray – MD & CEO

30 SEPTEMBER 2026





Disclaimer

IMPORTANT INFORMATION

The purpose of the presentation is to provide an update of the business of AnteoTech Ltd (ASX: ADO) (AnteoTech). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by AnteoTech and should not be relied upon as an independent source of information. Please contact AnteoTech and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Past performance is not indicative of future performance.

FORWARD-LOOKING STATEMENTS

The presentation may contain certain "forward-looking statements". Forward-looking statements can generally be identified by the use of forward-looking words such as "may", "will", "would", "could", "expect", "intend", "plan", "aim", "estimate", "target", "anticipate", "believe", "continue", "objectives", "outlook", "guidance" or other similar words, and include statements regarding AnteoTech's intent, belief or current expectations with respect to AnteoTech's business and operations, market conditions, results of operations and financial condition, capital adequacy and risk management. These forward-looking statements should not be relied upon as a representation or warranty, express or implied, as to future matters. Prospective financial information has been based on current expectations about future events and is, however, subject to risks, uncertainties, contingencies and assumptions that could cause actual results to differ materially from the expectations described in such prospective information. AnteoTech disclaims any obligation to update any forward-looking statement to reflect events or circumstances after the date of the presentation, subject to the disclosure requirements applicable to the Group.

NOT AN OFFER OF SECURITIES

This presentation should not be relied on as a recommendation or forecast by AnteoTech. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. The information in this presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account your financial objectives, situation or needs. Investors should consult with their own legal, tax, business and/or financial advisors in connection with any investment decision.

AnteoBind™ NXT, Anteo X®, Anteo S™ and Ultranode® are trademarks of AnteoTech. The use of registered and pending trademark symbols throughout the presentation is implied. All \$ quoted are AUD unless otherwise stated.




Today's Agenda

- Company Overview
- FY2026 Financial Performance
- FY2026 in Review
- What Next?
- Questions



FY2026 Annual Report released



**Advanced chemical
and material solutions**
in life sciences and
next-generation batteries

**One
proprietary
chemical
platform**

**Two global
markets**

**Multiple
commercial
pathways**

*Technology protected
through 17
granted patents*

*Advanced Battery
Technologies*

Ultranode™ 70, 95, X

*Anteo X
Anteo S
Anteo C
SiMRAX*

Life Sciences

*AnteoBind™/
AnteoBind NXT™*

- *Lateral Flow*
- *Multiplex*
- *CLIA*
- *ELISA*



Capital Structure and Corporate Overview

Market Capitalisation

\$56 m
as at 23 September 2026

Capital Structure (as at 23 September 2026)

Cash in Bank	\$11.2 million total as at 30 June 2026
Shares	3,265.1 million
Unlisted Options	233.5 million (7% expire in 2026, 65% in 2028). Employee/Director options 39%
Top 20 Holders	Hold 20% of shares

Directors



Glenda McLoughlin
Non-Executive Chair
Investment Banker with Morgan Stanley, Credit Suisse and Barclays. Commercial Advisor and ASX Founder. Energy and Infrastructure sector expertise.




Dr. Geoff Cumming
Non-Executive Director
Career spanning research to sales and marketing and Executive roles with Roche Also on INOVIQ Ltd (IIQ) Board. Biotechnology and Healthcare sector expertise.



Merrill Gray
Managing Director/CEO
Appointed 19 August 2025 (NED, 30 Jan., Interim MD 18 April 2025). ASX Founder and MD/CEO. Energy incl. Battery (CAM (LFP/LMFP), Graphite and Recycling) plus Hydrogen and Renewables experience.

Share Price – 6 months to 23 Sept 2026



Source: <https://www.asx.com.au/markets/company/ADO>



One surface chemistry, four detection platforms

Coordination bonding for antibody and protein immobilisation in IVD assays




Lateral flow

Antibody conjugation to latex for rapid tests



ELISA

Microplate activation for antibody and antigen coating




Chemiluminescence

Magnetic bead conjugation for CLIA immunoassays



Biosensors

Biomolecule immobilisation on sensor surfaces



AnteoBind™



Leading in High Silicon Anode Technology



ULTRANODE™

Application	Automotive & eVTOLs	3C Markets and Micro-mobility	M/UAS, eVTOL, Drones and Defence
Ultranode technology	Ultranode® X	Ultranode® 70	Ultranode® 95
Cycle life	High (>1,000 @ 80%)	Medium (>500 @ 80%)	Medium (>200 @ 80%)
Coating capacities	Medium (700-1,100 mAh/g)	Medium (700-1,100 mAh/g)	High (1,800-2,400 mAh/g)

Leading in Cross-linking Performance Additive



ANTEO C

Cross-linker for Primer Coatings
on Current Collector Foils



ANTEO S™

Cross-linker for Ceramic Coated
Separators (CCS)



ANTEO X®

Cross-linker for
Silicon Anodes



SIMRAX

Anteo X + SWCNT
Combination Product



Continued delivery on FY2026 Strategy

Source: Refer ASX Release dated 10 June 2025 "Strategic Review Outcomes"



Existing markets where opportunities will continue to be pursued



New opportunities being targeted and pursued

	Strategy	Life Sciences 1	Advanced Battery Technologies
 India	- Targeted sales growth through existing network expanding commercialisation pipeline. - Securing of strategic partnerships, profit repatriation model basis.	- Further expand Serum Institute of India relationship and secure additional similar customers. - Work with Austrade and Trade and Investment Queensland (TIQ)	Target E-Mobility and Wearables manufacturers Joint Venture and Joint Product Development (JDA).
 USA	- Expansion of our customer base - Attract strategic partner	Target the Point-of-Care Diagnostics, CLIA and ELISA markets.	- Target defence and security via drones and Unmanned Aerial Systems (UAS). Carbon Nanotube JDA.
 South Korea & Japan	- Expand our customer base/sales - Attract strategic partners	Distributors supporting growth Austrade and TIQ support	Distributors supporting growth Austrade and TIQ support
 Europe	- Expand existing customer base - Attract new partners	Global Life Sciences company engagement lateral flow, CLIA and ELISA.	WYON evaluation and validation and new customers


Global Diagnostic immunoassays market: US\$56 B p.a. sales revenue , 9% CAGR (2024) ^{1,2}

High silicon anode market: US\$540 M growing at 45% CAGR (2025)
Ceramic coated separators (CCS): US\$2 B growing at 21% CAGR (2024)³ Collector Foils: US\$21 B, Primer coatings/Anteo C ppt of this.

1 =Source: Markets and Markets May 2025 In Vitro Diagnostic Market: Growth, Size, Share and Trends and Confidential Pharmaceutical company
2= Precedence Research, Coherent Market Research
3 =<https://www.researchandmarkets.com/reports/6089608/ceramic-coated-separators-market-global>
4 = Refer 30 June 2026 ASX Announcement – New Product - Anteo C – Launched, Tested and Shipped etc.




Further progress against Strategy





Sales Revenue




Note:

* FY2025 included an additional Serum Institute of India (SII) payment of \$276,863

^ A further \$134,138 sale to SII was completed on 7 July 2026 and will be recognised in FY2027




Total Revenue



Note: A further \$134,138 sale to SII was completed on 7 July 2026 and will be recognised in FY2027




Operating Expense Reduction



Note: Excluding non-cash items such as depreciation and amortisation and share based payments



Losses




Note: A further \$134,138 sale to SII was completed on 7 July 2026 and will be recognised in FY2027



Commercialisation Focus

- ✓ Product and technology value proposition clarification and messaging
- ✓ Product and technology validation: Independent and in-house
 - ABT – Ultranode™ 95 at BIC, Ultranode™ X in-house (>850 mAh/g, 1,020 cycles at 80% capacity retention), Ultranode™ 70 commercial cell format validation by Wyon.
 - LS – White Paper (2) in-house
- ✓ Expanded Product portfolio - Market demand led
 - ABT – SiMRAX, Anteo S™, Anteo C
 - LS – CLIA, ELISA
- ✓ Significantly increased total addressable market: +\$US60 B
- ✓ Multiple sales channels activated
 - Partnerships, BD facilitators, Distributors
 - Conferences: Face to face customer engagement
 - Digital marketing campaigns
 - CRM and Sales team in place
- ✓ Record samples under evaluation



SPECIAL TEAM SUPPLIER






Growing Commercial Pipeline

@ 7 September 2026

Number of Companies





FY2027 Priority: Sales Conversion

Life Sciences

- Convert customer evaluations into sales - India, US, Europe, Japan and South Korea
- Progress CLIA strategic partnerships and market entry
- ELISA market entry



Advanced Battery Technologies

- Progress US Military drone Ultranode™ 95 JDAs - High powered batteries
- Convert Anteo S™, Anteo C and Anteo X® sales including in SiMRAX
- Progress Ultranode™ 70 commercial cell format evaluation and Consumer battery market opportunities
- Build out Airspeeder supply collaboration/partnerships



Corporate

- Maintain financial discipline
- Support sales pipeline conversion
- Progress Strategic Partnerships
- R&D tax rebate claim





Upcoming Commercial Engagement



From Lab to Clinical Trial:
**Paper-Based & Lateral Flow
Device Prototypes**

**PROF.
AMIT
ASTHANA**
NIPER HYDERABAD
National Institute of Pharmaceutical
Education & Research

AnteoTech Technical Webinar
Live presentation + Q&A

Thursday
6th October 2026
IST: 1:00 PM
AEST: 5:30 PM

HURRY. BOOK NOW!

National Institute of
Pharmaceutical Education
and Research (NIPER),
S.A.S. Nagar (Mohali),
Punjab, India



Anteo C

Current collectors
just got an upgrade!

Our water-based, PFAS-free cross-linker additive, stabilises primer coatings
and supports design choices that deliver improved performance.



Primer coating
(with Anteo C)

Current collector foil
(copper or aluminum)

BETTER INTERFACES
Achieve better electrochemical and mechanical
performance by leveraging more stable and improved
performance design choices

PFAS-FREE
Broad binder compatibility, allows use
of lower cost, eco friendly binders

DROP-IN
No added CAPEX

**THE BATTERY SHOW
NORTH AMERICA**

October 12 - 15, 2026
Detroit, Michigan
Team Australia Booth : 2204
Meet us at our booth

Reach out to learn more or request samples: contact@anteotech.com

North American
Battery Show
12-15 October 2026
Detroit, USA



Life Sciences

AnteoTech at MEDICA 2026

16 - 19 NOVEMBER 2026
DÜSSELDORF, GERMANY

MEDICA | WORLD FORUM
FOR MEDICINE



MEDICA, Dusseldorf, Germany



Questions

Contact:

Merrill Gray

investors@anteotech.com


+61 (07) 3219 0085

www.anteotech.com



Anatomy of a Lithium-ion Battery (LIB)

Electrochemical unit schematic plus electrolyte






The Drone, M/UAV and eVTOL Battery Market



A large market with several very different use or end application cases





Ultranode™ 95 – Superior Energy and Flight Time.

High capacity and cost-effective anode technology



Ultranode 95's unique Value Proposition



Superior Wh/kg at anode/cell level

>2,400mAh/g of anode coating capacity possible
At cell level, Specific Energy (Wh/kg) of >390 possible



Lowest \$/kWh silicon active material

Highly cost-effective anodes



Supply chain security

Existing silicon raw material supply from US, KR, EU




Highly customisable





Anteo S™

- Anteo S™ is used in ceramic coatings on separators to:
 - Improve thermal stability
 - Reduce thermal runaway and fires
 - Improve puncture resistance
- Anteo S™ potential lies in high volume sales for ESS and EVs



Source: Grand View Research (2024) - Battery Separator Market Size, Share & Trends Analysis Report by Material, by Application, by region, and Segment Forecasts, 2024–2032 and IDTechEX (2024) - Li-ion Battery Separator Technologies and Markets 2024–2034



Escondido, California (September 2024): A BESS fire at a substation resulted in significant damage. The incident involved overheating of battery cells.
Source: <https://eticaag.com/thermal-runaway-in-battery-energy-storage-systems-bess/>

Strategic Collaboration and Sales Agreement with





Leading in High Silicon Anode Technology



ULTRANODE™

Application	Automotive & eVTOLs	3C Markets and Micro-mobility	M/UAS, eVTOL, Drones and Defence
Ultranode technology	Ultranode® X	Ultranode® 70	Ultranode® 95
Cycle life	High (>1,000 @ 80%)	Medium (>500 @ 80%)	Medium (>200 @ 80%)
Coating capacities	Medium (700-1,100 mAh/g)	Medium (700-1,100 mAh/g)	High (1,800-2,400 mAh/g)
Supply Chain Options	Korea, China, US	Korea, China, US	Korea, China, US
Commercially scaled-up	✓	✓	✓
Engagement pathway	1. Technology partnership 2. Joint Development Agreements 3. Licensing	1. Ultranode samples 2. Ultranode + Cathode sample packs	Ultranode samples and Ultranode + Cathode sample packs



Leading in Cross-linking Performance Additive

C

ANTEO C

Cross-linker for Primer Coatings
on Current Collector Foils

Improved Performance Enabled by

- Improved metal foil adhesion
- Reduced interphase resistance

Improved Cost Efficiency

- Cheaper binders
- More water-based design choices

S

ANTEO STM

Cross-linker for Ceramic Coated
Separators (CCS)

Safer and Thinner Separators

- Reinforces ceramic coating, reducing potential thermal runaway and fires.

- Improves mechanical strength, puncture strength and thermal shut-down window

X

ANTEO X[®]

Cross-linker for
Silicon Anodes

Improved Performance

- Improved cycle life/capacity retention
- Reduced anode expansion

Improved Cost Efficiency

- Reduction in CNT content for high silicon anodes
- Reduction in binder content for high binder systems



SiMRAX

Anteo X + SWCNT
Combination Product

All-in-one solution for high Si anodes

- The only additive combining high quality carbon nanotube products with unique cross-linking agents
- World's most efficient binder strengthening additive. A single 'drop in' product that improves performance and reduces costs